Back to News
Apr 13, 2026 8:50 AM

Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares are up during Monday’s premarket session following a significant collaboration announcement with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).

Regeneron is a U.S.-based integrated biotechnology company, and Telix is a radiopharmaceutical company.

The partnership aims to develop next-generation radiopharmaceutical therapies, which could enhance Telix’s market position in precision oncology as the company leverages its expertise in radiopharmaceutical development and manufacturing capabilities while sharing commercialization costs and profits with Regeneron.

Partnership Combines Platforms And Scientific Capabilities

The collaboration combines Telix’s radiopharmaceutical development platform, global manufacturing capabilities, and supply chain infrastructure with Regeneron’s extensive biologics expertise, including bispecific antibody discovery.

The collaboration will include multiple solid tumor targets from Regeneron’s portfolio of antibodies, generated from ...